

**NATIONAL AERONAUTICS AND SPACE ADMINISTRATION**

[Notice: 24–050]

**Notice of Intent To Grant an Exclusive, Co-Exclusive or Partially Exclusive Patent License****AGENCY:** National Aeronautics and Space Administration (NASA).**ACTION:** Notice of intent to grant exclusive, co-exclusive or partially exclusive patent license.**SUMMARY:** NASA hereby gives notice of its intent to grant an exclusive, co-exclusive or partially exclusive patent license to practice the inventions described and claimed in the patents and/or patent applications listed in **SUPPLEMENTARY INFORMATION** below.**DATES:** The prospective exclusive, co-exclusive or partially exclusive license may be granted unless NASA receives written objections including evidence and argument, no later than August 28, 2024 that establish that the grant of the license would not be consistent with the requirements regarding the licensing of federally owned inventions as set forth in the Bayh-Dole Act and implementing regulations. Competing applications completed and received by NASA no later than August 28, 2024 will also be treated as objections to the grant of the contemplated exclusive, co-exclusive or partially exclusive license. Objections submitted in response to this notice will not be made available to the public for inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act.**Objections and Further Information:** Written objections relating to the prospective license or requests for further information may be submitted to Agency Counsel for Intellectual Property, NASA Headquarters at Email: [hq-patentoffice@mail.nasa.gov](mailto:hq-patentoffice@mail.nasa.gov). Questions may be directed to Phone: (202) 358–0646.**SUPPLEMENTARY INFORMATION:** NASA intends to grant an exclusive, co-exclusive, or partially exclusive patent license in the United States to practice the inventions described and claimed in: U.S. Patent No. 10,406,346 titled “DEVICE AND METHOD FOR HEALING WOUNDS” and U.S. Patent No. 11,298,526 titled “DEVICE FOR HEALING WOUNDS” to Kinnor Foundation, Inc. and its subsidiary Kinnor Technologies, LLC, each having its principal place of business in Orange Beach, Alabama. The fields of use may be limited. NASA has not yet made a final determination to grant the requested license and may deny the

requested license even if no objections are submitted within the comment period.

This notice of intent to grant an exclusive, co-exclusive or partially exclusive patent license is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). The patent rights in these inventions have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective license will comply with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Information about other NASA inventions available for licensing can be found online at <http://nasa.technology.gov>.**Trenton J. Roche,***Agency Counsel for Intellectual Property, National Aeronautics and Space Administration.*

[FR Doc. 2024–17960 Filed 8–12–24; 8:45 am]

**BILLING CODE 7510–13–P****POSTAL SERVICE****International Product Change—Priority Mail Express International, Priority Mail International & First-Class Package International Service Agreement****AGENCY:** Postal Service™.**ACTION:** Notice.**SUMMARY:** The Postal Service gives notice of filing a request with the Postal Regulatory Commission to add a Priority Mail Express International, Priority Mail International & First-Class Package International Service contract to the list of Negotiated Service Agreements in the Competitive Product List in the Mail Classification Schedule.**DATES:** *Date of notice:* August 13, 2024.**FOR FURTHER INFORMATION CONTACT:** Christopher C. Meyerson, (202) 268–7820.**SUPPLEMENTARY INFORMATION:** The United States Postal Service® hereby gives notice that, pursuant to 39 U.S.C. 3642 and 3632(b)(3), on August 7, 2024, it filed with the Postal Regulatory Commission a *USPS Request to Add Priority Mail Express International, Priority Mail International & First-Class Package International Service Contract 43 to Competitive Product List*. Documents are available at [www.prc.gov](http://www.prc.gov), Docket Nos. MC2024–482 and CP2024–489.**Christopher Doyle,***Attorney, Ethics and Legal Compliance.*

[FR Doc. 2024–17943 Filed 8–12–24; 8:45 am]

**BILLING CODE 7710–12–P****SECURITIES AND EXCHANGE COMMISSION**

[Release No. 34–100669; File No. SR-CboeBZX–2024–074]

**Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Its Fees Schedule**

August 7, 2024.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (“Act”),<sup>1</sup> and Rule 19b–4 thereunder,<sup>2</sup> notice is hereby given that on August 1, 2024, Cboe BZX Exchange, Inc. (the “Exchange” or “BZX”) filed with the Securities and Exchange Commission (“SEC” or “Commission”) the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.**I. Self-Regulatory Organization’s Statement of the Terms of Substance of the Proposed Rule Change**

Cboe BZX Exchange, Inc. (the “Exchange” or “BZX”) proposes to amend its Fees Schedule. The text of the proposed rule change is provided in Exhibit 5.

The text of the proposed rule change is also available on the Exchange’s website ([http://markets.cboe.com/us/equities/regulation/rule\\_filings/BZX/](http://markets.cboe.com/us/equities/regulation/rule_filings/BZX/)), at the Exchange’s Office of the Secretary, and at the Commission’s Public Reference Room.**II. Self-Regulatory Organization’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change**

In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.

<sup>1</sup> 15 U.S.C. 78s(b)(1).<sup>2</sup> 17 CFR 240.19b–4.